Effectiveness and Safety Profile of Oral Tofacitinib in Alopecia Areata: An Observational Study from a Tertiary Hospital.

Similarly, at 6 months, we observed a positive change in areata predictive score of 4.25 (>90% Severity of Alopecia Tool reduction) followed by 2.9 (50%-90%), 1.66 (10%-50%), and 1 (<10%).

Highly statistically significant results were achieved.

Autoimmune thyroid disease was the most common comorbidity.

Mild side effects were observed and managed with dose reduction.